Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMA study of pembrolizumab in locally advanced unresectable non-metastatic dMMR colorectal cancer
2021-005731-23Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in colorectal cancer (CRC), colon adenocarcinoma and rectal adenocarcinoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Objective response rate. Started Aug 2022; status: active.
02
Drugs
03
Conditions
colorectal cancer (CRC)colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2021-005731-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005731-23.